вторник, 14 февраля 2017 г.

GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming

GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming


The restructuring set in motion in 2015 continues to take hold, and revenue is on the rise. But management tamped down the enthusiasm by warning that the long-awaited generic competition for its most important drug, Advair, is likely to appear this year.



from Biotech News